Shares of Gilead Sciences ( GILD 7.46%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the big ...

Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My ...

Gilead Sciences faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033. Check out my ...

Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...

Gilead Sciences reported its fourth-quarter financial results after Tuesday's closing bell. Here's a look at the highlights ...

Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025.

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Piper Sandler raised the firm’s price target on Gilead (GILD) to $110 from $105 and keeps an Overweight rating on the shares after the company ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...